The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index; 23 of the 37 sources its claims cite were checked for support.
Characterization of anti-AAV2 neutralizing antibody levels in sheep prior to and following intravitreal AAV2.7m8 injection
Open accessAbstract
Gene augmentation therapy is a promising treatment for incurable, blinding inherited retinal diseases, and intravitreal delivery is being studied as a safe alternative to subretinal injections. Adeno-Associated Viruses (AAV) are commonly-used vectors for ocular gene augmentation therapy. Naturally occurring pre-operative exposure and infection with AAV could result in presence of neutralizing antibodies (NAB's) in patients' serum, and may affect the safety and efficacy of treatment. Our aim was to characterize the humoral response against AAV pre- and post-intravitreal delivery of AAV2.7m8 vectors in a naturally-occurring sheep model of CNGA3 achromatopsia. Serial serum neutralization assays were performed to screen sheep for pre-exiting anti-AAV2 NAB's, and to assess the effect of intravitreal AAV2.7m8 injection on post-operative NAB titers and intraocular inflammation in sheep. The effect of viral dose and transgene type were also assessed. Serological screening revealed pre-operative seropositivity in 21.4% of animals, with age being a risk factor for the presence of anti-AAV2 NAB's. NAB titers increased following intravitreal AAV administration in the majority of sheep. There was no significant difference in the degree of post-operative serum neutralization between pre-operatively seronegative sheep and those with pre-existing antibodies. However, only sheep with pre-existing antibodies presented with signs of post-operative inflammation. We conclude that pre-existing anti-AAV2 NAB's do not affect the level of post-operative NAB titers; however, they increase the risk of post-operative ocular inflammation. Our results could have implications for the management of AAV-mediated ocular gene therapies, a technology being increasingly studied and used in patients.
Overview
CoChat Summary
TL;DR
In a naturally occurring sheep model of CNGA3 achromatopsia, pre-existing anti-AAV2 neutralizing antibodies were found in 21.4% of screened sheep and increased with age. After intravitreal AAV2.7m8 injection, NAB titers rose in most sheep, but only pre-operatively seropositive sheep showed post-operative ocular inflammation.
Key findings
- Among 70 screened sheep, 15 (21.4%) were pre-operatively seropositive for anti-AAV2 NABs; seropositivity was 55% (11/20) in sheep older than one year versus 8% (4/50) in younger sheep, with a 6.875 relative risk in older animals.
- Following intravitreal AAV2.7m8 injection, NAB titers increased in 9/12 sheep; the seronegative group showed a significant post-operative increase at 12 weeks, but there was no significant difference in post-operative NAB titers between pre-operatively seronegative and seropositive sheep.
- Only sheep with pre-existing anti-AAV2 antibodies presented with post-operative inflammatory signs; inflammation grading differed significantly between seropositive and seronegative groups at 7–10 days post-operatively (p = 0.032).
- No correlation was found between total viral vector dose injected and the degree of serum neutralization at 12 weeks post-operatively.
Methods
- Retrospective serological and clinical analysis of sheep from the Volcani Center experimental flock: 70 ewes (63 wild type, 7 day blind) were screened for pre-existing anti-AAV2 NABs, and 12 sheep underwent uni- or bilateral intravitreal injection of AAV2.7m8 with different promoters, transgenes, and doses (Table 1).
- Serum neutralization assays used HEK293T cells and AAV2.7m8-CMV-luciferase; samples reducing luminescence below 50% were considered seropositive. Clinical ophthalmic examinations graded inflammatory findings on a 0–4 scale.
- Statistical analysis used Shapiro-Wilk, Student’s t test, repeated measures ANOVA, and linear regression, with p < 0.05 considered significant.
Limitations
- The paper states that sample size is a major limitation, including too few animals per transgene to assess transgene effects and unequal unilateral versus bilateral injections preventing analysis of number of eyes injected.
- The paper states that NAB detection used a single AAV serotype, that cross-reactivity with other serotypes could affect results, and that seroprevalence depends on the assay and definition of seropositivity.
- The paper states that most seropositive sheep received non-coding vectors, preventing correlation between serological response and gene expression; it also notes the study was retrospective and the investigator was not blinded to group allocation.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
17 Valid · 0 Not valid · 5 Not checked · 46 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Seropositivity rate in our cohort was comparatively lower than that found in healthy human populations and in clinical trial patients, which ranged between 22-90% in different reports [7, 23, 24].”
§ Characterization of anti-AAV2 neutralizing antibody levels in sheep prior to and following intravitreal AAV2.7m8 injection > Discussion
What the sources say
- Not checked — no full text of the sourcecites [7] Boutin S, Monteilhet V, Veron P, Leborgne C, Benveniste O, Montus MF, et al. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum Gene Ther. 2010;21:704–12. source
- Partly supportedcites [23] Calcedo R, Vandenberghe LH, Gao G, Lin J, Wilson JM. Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J Infect Dis. 2009;199:381–90. sourceExperimental — accuracy not yet measured
The Discussion reports anti-AAV2 neutralizing-antibody prevalence of 30% in the United States and 60% in Africa, supporting the comparison with human populations. It does not establish the stated 22–90% range or report seropositivity among clinical-trial patients; the sheep-cohort result belongs to the citing study. (LLM, conf=0.86)
- Partly supportedcites [24] Louis Jeune V, Joergensen JA, Hajjar RJ, Weber T. Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy. Hum Gene Ther Methods. 2013;24:59–67. sourceExperimental — accuracy not yet measured
Table 1 (Introduction; page unavailable) reports human anti-AAV neutralizing-antibody prevalence values of both 22% and 90% across studies, supporting those figures as examples for comparison. But it also lists values below 22% and above 90%, so 22–90% is not the full range in this source. The sheep-cohort rate is the citing authors’ own finding, not a finding attributed to this paper. (LLM, conf=0.84)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“A significant barrier to effective intraocular rAAV gene delivery is the interaction of the vector with the host’s immune system [5].”
§ Characterization of anti-AAV2 neutralizing antibody levels in sheep prior to and following intravitreal AAV2.7m8 injection > Introduction
What the sources say
- Supportedcites [5] Ail D, Malki H, Zin EA, Dalkara D. Adeno-Associated Virus (AAV) - Based Gene Therapies for Retinal Diseases: Where are We? Appl Clin Genet. 2023;16:111–30. source
The “Challenges with AAVs” section says anti-AAV antibodies can reduce gene-therapy efficacy and that AAVs can trigger an immune response in the eye. “Strategies to Overcome Immune Responses” states that adverse immune outcomes from AAV delivery to the eye include reduced efficacy and clearance of transduced cells. These passages support the claimed barrier to intraocular delivery. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“because a high level of naturally occurring anti-AAV2 antibodies was previously reported in sheep [22].”
§ Characterization of anti-AAV2 neutralizing antibody levels in sheep prior to and following intravitreal AAV2.7m8 injection > Introduction
What the sources say
- Supportedcites [22] Tellez J, Van Vliet K, Tseng YS, Finn JD, Tschernia N, Almeida-Porada G, et al. Characterization of naturally-occurring humoral immunity to AAV in sheep. PLoS One. 2013;8:e75142. source
The Results section reports naturally occurring antibodies to AAV2 in the sheep tested, including one sheep with a very high IgG level against all six AAV serotypes. Antibody levels varied substantially among the six sheep, so the reported high level does not describe every animal. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The effect of age on seropositivity is consistently reported both in the human population and in non-human primates [25, 26].”
§ Characterization of anti-AAV2 neutralizing antibody levels in sheep prior to and following intravitreal AAV2.7m8 injection > Discussion
What the sources say
- Not checked — no full text of the sourcecites [25] Calcedo R, Morizono H, Wang L, McCarter R, He J, Jones D, et al. Adeno-associated virus antibody profiles in newborns, children, and adolescents. Clin Vaccin Immunol. 2011;18:1586–8. source
- Partly supportedcites [26] Perocheau DP, Cunningham S, Lee J, Antinao Diaz J, Waddington SN, Gilmour K, et al. Age-Related Seroprevalence of Antibodies Against AAV-LK03 in a UK Population Cohort. Hum Gene Ther. 2019;30:79–87. sourceExperimental — accuracy not yet measured
The Results section, “Anti-AAV-LK03 IgG and Nab rates in humans vary with age” (page unavailable), reports age-related differences in human seroprevalence. The Methods section, “Samples,” and the nonhuman-primate Results section (pages unavailable) describe testing only juvenile macaques and do not establish an effect of age within primates. The source therefore supports the human part, but not the claim that the age effect is reported in both populations. (LLM, conf=0.86)
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, compared to SR delivery, IVT injections may trigger a more robust immune response against the rAAV vector because of its closer proximity to the vascular system, the larger doses required to compensaet for dilution in the vitreous, and the lack of a blood retinal barrier that exists in the SR but not in the IVT space [6].”
§ Characterization of anti-AAV2 neutralizing antibody levels in sheep prior to and following intravitreal AAV2.7m8 injection > Introduction
What the sources say
- Partly supportedcites [6] Kotterman MA, Yin L, Strazzeri JM, Flannery JG, Merigan WH, Schaffer DV. Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates. Gene Ther. 2015;22:116–26. sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
39 more claims · 2 with their cited sources checked
Create a free account to see all 68 claims and every source verdict.
- Probably not a substantial claim. 17
- It may state two separate claims as one. 13
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Antibodies could contribute to the innate immune response through antibody-opsonisation and complement activation (Fig. 3) and therefore intraocular inflammation (Ross et al., 2024).”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Ross et al., 2024
Experimental — accuracy not yet measured
Citations
Cites
Adeno-associated virus vector as a platform for gene therapy delivery
Wang, D., Tai, P. W. L., & Gao, G. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0012-9 · Cited by 2,444
Boutin, S., Monteilhet, V., Veron, P., Leborgne, C., Benveniste, O., Montus, M. F., & Masurier, C. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.182 · Cited by 970
Maguire, A. M., High, K. A., Auricchio, A., Wright, J. F., Pierce, E. A., Testa, F., Mingozzi, F., Bennicelli, J. L., Ying, G.-S., Rossi, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61836-5 · Cited by 865
Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses
Calcedo, R., Vandenberghe, L. H., Gao, G., Lin, J., & Wilson, J. M. (2009) · The Journal of Infectious Diseases · doi:10.1086/595830 · Cited by 808
Ocular immune privilege: therapeutic opportunities from an experiment of nature
Streilein, J. W. (2003) · Nature Reviews Immunology · doi:10.1038/nri1224 · Cited by 807
High-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors
Petrs-Silva, H., Dinculescu, A., Li, Q., Min, S.-H., Chiodo, V., Pang, J.-J., Zhong, L., Zolotukhin, S., Srivastava, A., Lewin, A. S., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2008.269 · Cited by 398
AAV2 Gene Therapy Readministration in Three Adults with Congenital Blindness
Bennett, J., Ashtari, M., Wellman, J., Marshall, K. A., Cyckowski, L. L., Chung, D. C., McCague, S., Pierce, E. A., Chen, Y., Bennicelli, J. L., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3002865 · Cited by 395
Pre-existing Anti–Adeno-Associated Virus Antibodies as a Challenge in AAV Gene Therapy
Louis Jeune, V., Joergensen, J. A., Hajjar, R. J., & Weber, T. (2013) · Human Gene Therapy Methods · doi:10.1089/hgtb.2012.243 · Cited by 358
Adeno-Associated Virus Antibody Profiles in Newborns, Children, and Adolescents
Calcedo, R., Morizono, H., Wang, L., McCarter, R., He, J., Jones, D., Batshaw, M. L., & Wilson, J. M. (2011) · Clinical and Vaccine Immunology · doi:10.1128/cvi.05107-11 · Cited by 345
Cukras, C., Wiley, H. E., Jeffrey, B. G., Sen, H. N., Turriff, A., Zeng, Y., Vijayasarathy, C., Marangoni, D., Ziccardi, L., Kjellstrom, S., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.05.025 · Cited by 268
Cited by
Purdy, R., John, M., Bray, A., Clare, A. J., Copland, D. A., Chan, Y. K., Henderson, R. H., Nerinckx, F., Leroy, B. P., Yang, P., et al. (2025) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2025.101354 · Cited by 24
Alvisi, M., Roberts, L., Roessig, L., Balderson, D. E., Sanganalmath, S. K., Braun, M., Gordon, S. N., Lacey, S. F., Pandya, P., & Hajjar, R. J. (2026) · Human Gene Therapy · doi:10.1177/10430342261430244 · Cited by 2
“69 Further preclinical data from NHPs showed similar kinetics for the onset of anti-AAV5 Ab response following IV administration of valoctocogene roxaparvovec (Roctavian) regardless of pre-existing Ab status.”
Label-Free Quantification of Virus Titer Using Machine Learning-Enhanced Immunosensors
Shukla, R. P., Sun, H., Wang, J., Twiddy, J. S., Shastry, S., Hosseini, M., Menegatti, S., & Daniele, M. A.-A. (2026) · IEEE Sensors Journal · doi:10.1109/jsen.2026.3681515
“…properties as a vector with extensive clinical development history (e.g., Luxturna for the treatment of inherited retinal dystrophy [22], [23], [24], [25] and for which high-affinity anti-AAV2 antibodies suitable for immunosensor applications are commercially available [26], [27].”
Metadata
- Authors
- Ross, M., Sade, K., Obolensky, A., Averbukh, E., Desrosiers, M., Rosov, A., Dvir, H., Gootwine, E., Banin, E., Dalkara, D., & Ofri, R.
- Affiliations
- Agricultural Research Organization (IL)
- Hebrew University of Jerusalem (IL)
- Centre National de la Recherche Scientifique (FR)
- Corresponding author
- Ofri, Ron
- Venue
- Gene Therapy
- Published
- 2024-10-29
- Volume
- 31
- Issue
- 11-12
- Pages
- 580-586
- ISSN
- 0969-7128 (ISSN-L)
- 1476-5462
- PMC
- PMC11576537
- OpenAlex
- W4403876117
- Cited by
- 3
- References
- 43
- Citations by year
- 2026: 2 · 2025: 1
- FWCI
- 0.79
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Gene Therapy (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Ministry of Health, State of Israel (3-0000-15068)
- Israel Science Foundation (1257/15)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- adeno-associated virus type 2, neutralizing antibodies, intravitreal gene therapy, sheep model, humoral immune response, age as risk factor, viral dose
- MeSH terms
- Dependovirus, Animals, Antibodies, Viral, Genetic Vectors, Sheep, Genetic Therapy, Transgenes, Antibodies, Neutralizing, Intravitreal Injections
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-01, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-01 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Characterization of anti-AAV2 neutralizing antibody levels in sheep prior to and following intravitreal AAV2.7m8 injection. https://app.cochat.ai/papers/10.1038/s41434-024-00495-5
- The paper
- Ross, M., Sade, K., Obolensky, A., Averbukh, E., Desrosiers, M., Rosov, A., Dvir, H., Gootwine, E., Banin, E., Dalkara, D., & Ofri, R. (2024). Characterization of anti-AAV2 neutralizing antibody levels in sheep prior to and following intravitreal AAV2.7m8 injection. Gene Therapy. https://doi.org/10.1038/s41434-024-00495-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.